ETFIQData as of Nov 18, 2026. · etfiq.com/funds/fpxe

FPXE Fact Sheet: First Trust IPOX Europe Equity Opportunities ETF

Share
$30.45
close, Nov 18, 2026

Over the year to Nov 18, 2026, FPXE returned +4.0% in total and charged 0.70% a year.

1-year total return
+4.0%
to Nov 18, 2026
Expense ratio
0.70%
a year
Net assets
$4.6m
on Nov 17, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

FPXE $10,401 +4.0% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month−1.3%
3 months−9.6%
Year to date−1.8%
1 year+4.0%
3 years+51.9%
5 years+1.4%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Roche Holding AG8.08%
Swedish Orphan Biovitrum AB6.91%
Ascendis Pharma A/S6.68%
BAWAG Group AG6.50%
Nordnet AB (publ)6.11%
Lottomatica Group SpA5.17%
Technoprobe SpA4.20%
Arm Holdings Plc3.24%
Andritz AG3.07%
Sandoz Group AG2.88%

FPXE top ten by weight, 52.8% of the fund, of its 101 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the IPOX -100 Europe Index · First traded Oct 5, 2018 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, FPXE Fact Sheet: First Trust IPOX Europe Equity Opportunities ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/fpxe/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/fpxe.